Camilla Zecchetto
University of Verona
FrizzledCancerAdipogenesisInternal medicineWnt signaling pathwayOncologySmall hairpin RNAImmunologyObservational studyPerformance statusMetastasisDiseasePancreatic cancerGemcitabineIrinotecanAngiogenesisFluorouracilOxaliplatinAdenocarcinomaKRASTargeted therapyRSPO1RegimenPopulationLocally advancedIn patientCancer researchColorectal cancerClinical trialInterleukin 8MedicineParacrine signallingFibroblast growth factor receptorBiology
23Publications
7H-index
208Citations
Publications 23
Newest
#1Davide MelisiH-Index: 31
Last. Giovanni ButturiniH-Index: 51
view all 21 authors...
Abstract Background Pancreaticoduodenal cancer (PDC) is a group of malignant tumors arising in the ampullary region, which lack approved targeted therapies for their treatment. Methods This retrospective, observational study is based on Secondary Data Use (SDU) previously collected during a multicenter collaboration, which were subsequently entered into a predefined database and analyzed. FoundationOne CDx or Liquid, a next-generation DNA sequencing (NGS) service, was used to identify genomic al...
Source
#1Valeria Merz (University of Verona)H-Index: 9
#2Marina Gaule (University of Verona)H-Index: 3
Last. Davide Melisi (University of Verona)H-Index: 31
view all 13 authors...
Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more than 90% in certain cancer types such as pancreatic adenocarcinoma. Although historically considered to be undruggable, a particular KRAS mutation, the G12C variant, has recently emerged as an actionable alteration especially in non-small cell lung cancer (NSCLC). KRASG12C and pan-KRAS inhibitors are being tested in cli...
1 CitationsSource
#1Davide Melisi (University of Verona)H-Index: 31
#2Do-Youn Oh (Seoul National University Hospital)H-Index: 56
Last. Rocio Garcia-CarboneroH-Index: 28
view all 19 authors...
Background We assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refractory metastatic pancreatic cancer previously treated with ≤2 systemic regimens. Methods This was a two-part, single-arm, multinational, phase Ib study. In a dose-finding phase, escalating oral doses of galunisertib were co-administered on days 1–14 with...
7 CitationsSource
#1Valeria MerzH-Index: 9
#2Camilla ZecchettoH-Index: 7
Last. Davide MelisiH-Index: 31
view all 3 authors...
The prognosis of patients affected by cholangiocarcinoma is classically poor. Until recently, chemotherapeutic drugs were the only systemic treatment option available, leading to an overall survival lower than 1 year. In recent decades, different genetic alterations have been identified as playing a key role in the oncogenic signaling. A subgroup of intrahepatic cholangiocarcinoma is characterized by FGFR family mutations, more frequently represented by gene fusions of FGFR2. Based on the result...
6 CitationsSource
#1Ian M. Silverman (Wilmington University)H-Index: 1
#1Ian M. Silverman (Incyte)H-Index: 16
Last. Timothy Burn (Incyte)H-Index: 32
view all 10 authors...
Pemigatinib, a selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase 2 study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Eligibility for FIGHT-202 was assessed using genomic profiling; here, these data were utilized to characterize the genomic landscape of cholangiocarcinoma, and to uncover unique molecular features of patients harboring F...
12 CitationsSource
Source
#1Francesca Simionato (University of Verona)H-Index: 14
#2Camilla Zecchetto (University of Verona)H-Index: 7
Last. Davide Melisi (University of Verona)H-Index: 31
view all 34 authors...
Background Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that often impairs postoperative treatment, and the common metastatic relapse limit the overall clinical outcomes achieved with this strategy. Polychemotherapeutic combinations are valid options for postoperative treatment in patients with good performance ...
1 CitationsSource
#1Serena Zuliani (University of Verona)H-Index: 2
#2Ilaria Zampiva (University of Verona)H-Index: 4
Last. Michele Milella (University of Verona)H-Index: 50
view all 55 authors...
Abstract Background On February 23rd, the 1st case of SARS-CoV-2 infection was diagnosed at the University Hospital Trust of Verona, Italy. On March 13th, the Oncology Section was converted into a 22-inpatient beds COVID unit and we reshaped our organization to face SARS-CoV-2 epidemic, while maintaining oncological activities. Methods We tracked down: i) volumes of oncological activities (January 1st - March 31st, 2020 versus the same period of 2019), ii) patients' and caregivers' perception, i...
6 CitationsSource
#1Valeria MerzH-Index: 9
#2Camilla ZecchettoH-Index: 7
Last. Davide Melisi (University of Verona)H-Index: 31
view all 19 authors...
Background:Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted ...
7 CitationsSource
#1Valeria Merz (University of Verona)H-Index: 9
#2Alessandro Cavaliere (University of Verona)H-Index: 6
Last. Davide Melisi (University of Verona)H-Index: 31
view all 9 authors...
Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An increasing number of patients are eligible for second-line therapy, but the best regimen is still controversial. This study aimed to evaluate the efficacy of oxaliplatin-based compared to irinotecan-based therapies in this setting. 181 advanced pancreatic cancer patients consecutively treated in three centers with a second-line therapy pro...
5 CitationsSource